思创医惠科技股份有限公司（以下简称"公司"）董事会于 2023 年 8 月 11 日收到公司副总经理、董事会秘书薛起玮女士提交的书面辞职报告。薛起玮女士 因工作原因申请辞去公司董事会秘书职务，辞职后仍担任公司副总经理。该辞职 报告自送达董事会之日起生效。薛起玮女士原定任期届满日为 2024 年 8 月 17 日。截至本公告日，薛起玮女士持有公司法人股东杭州思创医惠集团有限公司（以 下简称"医惠集团"）1.38%股权，医惠集团持有公司股份 9,295,817 股，占公 司总股本的 1.08%，其未直接持有公司股份，且不存在应履行而未履行的承诺， 辞职不会影响公司相关工作的正常进行。 | 证券代码：300078 | 证券简称：思创医惠 | 公告编号：2023-090 | | --- | --- | --- | | 债券代码：123096 | 债券简称：思创转债 | | 思创医惠科技股份有限公司 关于公司董事会秘书辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2023 年 8 月 11 日 1 为保证公司董事会工作的正常进行，根据《深圳证券交易所创业板 ...

3 .公司5月18日发布公告，计划回购注销4492000股限制性股 票，将减少公司注册资本。触及《公司法》第177条，债权人有权 要求公司清偿债务。目前公司可转债余额约8.17亿元，请问公司是 否有足够的现金予以支付？ | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 线上参与公司2022年度网上业绩说明会的全体投资者 | | 时间 | 2023年05月23日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | 董事长 上市公司接待人员姓名 | 章笠中 | | | 联席董事长、董事会秘书（代行） 朱以明 | | | 董事、总经理 华松鸳 | | | 财务总监 陈云昌 | | | 独立董事 梁立 | | | 保荐代表人 马齐玮 | | 投资者关系活动主要内容 介绍 | 1 .思创医惠发行可转债会不会有逾期，不还钱？公司今年会不 ...

| 证券代码：300078 | 证券简称：思创医惠 | 公告编号：2023-054 | | --- | --- | --- | | 债券代码：123096 | 债券简称：思创转债 | | 思创医惠科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 思创医惠科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日在 巨潮资讯网（http://www.cninfo.com.cn）上披露了《2022 年年度报告》及《2022 年年度报告摘要》。为便于广大投资者更加全面深入地了解公司经营业绩、发展 战略等情况，公司定于 2023 年 5 月 23 日（星期二）15:00-17:00 在"价值在线" （www.ir-online.cn）举行思创医惠科技股份有限公司 2022 年度网上业绩说明 会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。现将有关事项公 告如下： 一、说明会召开的时间、地点和方式 会议召开时间：2023 年 5 月 23 日（星期二）15:00-17:00 会议召开地点 ...

Financial Performance - The company reported significant losses due to extended delivery cycles and increased costs, resulting in a substantial decline in performance [3]. - The company's operating revenue for 2022 was ¥1,108,893,359.21, representing a 15.32% increase compared to ¥961,549,939.60 in 2021 [27]. - The net profit attributable to shareholders was -¥881,508,508.17 in 2022, a decrease of 21.25% from -¥727,023,296.46 in 2021 [27]. - The cash flow from operating activities showed a net outflow of -¥105,192,708.38, a significant decline of 178.48% compared to a positive cash flow of ¥134,041,273.63 in 2021 [27]. - The total assets at the end of 2022 were ¥3,648,625,453.19, down 24.98% from ¥4,863,530,760.78 at the end of 2021 [27]. - The net assets attributable to shareholders decreased by 39.84% to ¥1,311,618,631.90 at the end of 2022 from ¥2,180,294,683.75 at the end of 2021 [27]. - The basic and diluted earnings per share for 2022 were both -¥1.06, a decline of 21.84% from -¥0.87 in 2021 [27]. - The company reported a quarterly revenue of ¥99,866,650.86 in Q4 2022, a significant drop compared to Q1 2022 revenue of ¥386,055,693.36 [29]. - The company experienced a net loss of -¥886,191,718.12 in Q4 2022, following a net profit of ¥30,953,691.43 in Q1 2022 [29]. - The company received government subsidies amounting to ¥11,530,082.86 in 2022, down from ¥18,849,936.02 in 2021 [33]. - The total non-recurring gains and losses for 2022 amounted to ¥18,921,990.29, a decrease from ¥75,592,354.95 in 2021 [34]. Business Focus and Innovation - The core business focuses on smart healthcare, leveraging IoT, big data, AI, and blockchain technologies, with services applied in over 1,600 medical institutions across China [6]. - The company has established over 10 technology innovation R&D centers and participated in more than 20 national major research projects [6]. - The company plans to continue focusing on innovation, differentiated products, and standardized systems to enhance customer experience [6]. - The smart healthcare industry in China is projected to reach an IT expenditure market size of CNY 104.15 billion by 2024, with a compound annual growth rate (CAGR) exceeding 15% for healthcare application software solutions [38]. - The company aims to leverage five core technologies—IoT, artificial intelligence, big data interaction, microservices architecture, and blockchain—to drive innovation in smart healthcare services [42]. - The company has developed a series of integrated clinical electronic medical record systems, enhancing operational efficiency in hospitals [43]. - The company is focusing on expanding its software solutions, including the Medical Data Visualization Engine System V1.0, to improve data accessibility [54]. - The company is committed to ongoing research and development, with a focus on innovative healthcare solutions [71]. Market Trends and Opportunities - The regional healthcare informationization market is projected to grow from RMB 46.6 billion in 2021 to RMB 124.5 billion by 2025, with a compound annual growth rate of 27.9% [7]. - The company has established long-term strategic partnerships with international firms such as Huawei, H3C, Baidu, and IBM, enhancing its position as a leading provider of smart healthcare solutions in China [42]. - The government has introduced multiple policies to promote the development of smart healthcare, creating new opportunities for the industry [40]. - The RFID industry in China is expected to grow significantly, with an estimated market value exceeding CNY 35 billion by 2025, following a decline in 2020 [47]. - The company is recognized as one of the top three global players in the RFID market, maintaining a leading market share for its basic and ultra-high frequency RFID products [48]. Research and Development - The company invested a total of 203.77 million yuan in R&D, accounting for 18.38% of its operating revenue [63]. - The company has obtained a total of 7 invention patents, 38 utility model patents, and 13 design patents during the reporting period, showcasing its commitment to innovation [68]. - The company has launched new products such as the intelligent anti-theft management system and health cloud platform, enhancing its product portfolio [71]. - The company has developed over 60 single-disease data resource libraries and applications based on its THINKGO medical AI cognitive engine [74]. - The company has completed the development of a Bluetooth-enabled temperature monitoring system, aimed at improving product competitiveness in the wearable device market [112]. Strategic Partnerships and Collaborations - The company has established long-term stable partnerships with over 300 clients and agents, exporting products to more than 70 countries and regions, including Europe, America, the Middle East, and Southeast Asia [49]. - The company is actively pursuing strategic acquisitions to enhance its technological capabilities and market reach [71]. - The company has formed a strategic partnership with Yunhai Chain Holdings to integrate smart medical services with blockchain technology [150]. - The company emphasizes collaboration with various healthcare partners to create an inclusive and open ecosystem for smart healthcare services [155]. Corporate Governance and Management - The company has no controlling shareholder or actual controller, maintaining independence in operations, assets, and finances [175]. - The board of directors consists of 7 members, including 3 independent directors, meeting legal requirements for governance structure [176]. - The supervisory board held 8 meetings during the reporting period, overseeing major transactions and ensuring compliance with regulations [178]. - The company has established a fair and effective performance evaluation and incentive mechanism for senior management, combining base salary with annual performance assessments [179]. - The company strictly adheres to information disclosure obligations, ensuring timely and accurate reporting of financial and operational information [180]. Challenges and Risks - The company faces intensified competition in the IoT and smart healthcare sectors, necessitating continuous technological advancements and market expansion strategies to maintain its competitive edge [158]. - The company is under investigation by the China Securities Regulatory Commission for alleged information disclosure violations, which may impact its operations and reputation [169]. - The company is actively managing foreign exchange risks due to significant export proportions in its business, employing suitable hedging tools and insurance to mitigate potential losses [163]. Future Outlook - The company aims to enhance its market presence through the introduction of new products and technologies in the healthcare sector [30]. - The company is strategically positioning itself for future growth by expanding its software capabilities and exploring new market opportunities [62]. - The company is committed to improving its research and development capabilities to keep pace with rapid technological advancements in the healthcare industry [159].

Financial Performance - The company's revenue for Q1 2023 was ¥235,156,485.53, a decrease of 39.09% compared to ¥386,055,693.36 in the same period last year[5] - The net loss attributable to shareholders was ¥76,663,823.76, representing a decline of 347.67% from a profit of ¥30,953,691.43 in the previous year[5] - The company reported a basic and diluted earnings per share of -¥0.09, down 325.00% from ¥0.04 in the same period last year[5] - Net profit for Q1 2023 was a loss of CNY 80,567,340.48, compared to a profit of CNY 29,120,333.27 in Q1 2022, indicating a significant decline[26] - The total comprehensive income for Q1 2023 was -85,664,791.57 CNY, compared to 32,450,227.88 CNY in Q1 2022, indicating a substantial decrease in overall performance[27] - Basic and diluted earnings per share for Q1 2023 were both -0.09 CNY, compared to 0.04 CNY in the same period last year, reflecting a downturn in profitability[27] Cash Flow - The net cash flow from operating activities improved to ¥48,334,123.98, a significant increase of 133.80% compared to a negative cash flow of ¥143,017,748.92 in the same period last year[5] - The operating cash flow for Q1 2023 was 48,334,123.98 CNY, a recovery from a negative cash flow of -143,017,748.92 CNY in the previous year[30] - The company reported cash inflows from operating activities totaling 317,208,994.01 CNY, slightly up from 310,194,960.39 CNY in the previous year[30] - The cash outflow from investing activities was 357,660,058.09 CNY, compared to 99,748,655.31 CNY in the same period last year, indicating increased investment expenditures[30] - The net cash flow from financing activities was -103,463,332.98 CNY, a significant drop from a positive cash flow of 166,912.16 CNY in Q1 2022[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,514,161,875.38, down 3.69% from ¥3,648,625,453.19 at the end of the previous year[5] - Total assets as of March 31, 2023, were CNY 3,514,161,875.38, down from CNY 3,648,625,453.19 at the beginning of the year, a decrease of 3.7%[23] - Total liabilities decreased to CNY 2,264,586,341.85 from CNY 2,317,463,787.14, a reduction of 2.3%[23] - The company’s total equity decreased to CNY 1,249,575,533.53 from CNY 1,331,161,666.05, a decline of 6.1%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 50,256[10] - The top shareholder, Lu Nan, holds 7.26% of the shares, amounting to 62,739,500 shares[10] - As of March 31, 2023, the company's stock repurchase account held 33,464,340 shares, accounting for 3.87% of the total share capital[11] - The company reported a total of 88,310,537 shares under lock-up agreements, with specific release conditions for different shareholders[13] - The company’s major shareholders include individuals and entities with significant stakes, such as Zhang Lichun and Hangzhou Botai Investment Management Co., Ltd.[11] Investment and Guarantees - The company issued 8,167,260 convertible bonds with a remaining amount of RMB 816,726,000 as of March 31, 2023[19] - The total balance of guarantees provided by the company and its subsidiaries amounted to RMB 635.50 million, representing 48.45% of the latest audited net assets[20] - The company’s full subsidiary, Yihui Technology Co., Ltd., provided guarantees totaling RMB 380 million, which is 28.97% of the latest audited net assets[20] - The company completed the interest distribution for its convertible bonds, with a total interest payment of RMB 4,900,362 for the period[15] Operational Metrics - Total operating revenue for Q1 2023 was CNY 235,156,485.53, a decrease of 38.9% compared to CNY 386,055,693.36 in the same period last year[25] - Total operating costs for Q1 2023 were CNY 304,851,282.96, down from CNY 363,464,962.64, reflecting a reduction of 16.2%[26] - The company reported a significant increase in research and development expenses, totaling CNY 33,460,399.84, compared to CNY 31,781,348.68 in the previous year, an increase of 5.3%[26] Other Financial Metrics - The weighted average return on equity was -6.03%, a decrease of 7.44% from 1.41% in the previous year[5] - Cash and cash equivalents at the end of Q1 2023 were CNY 456,724,688.34, down from CNY 470,050,480.40 at the beginning of the year, a decrease of 2.3%[22] - Accounts receivable decreased to CNY 678,776,186.86 from CNY 746,901,150.03, a decline of 9.1%[22] - The company’s long-term investments decreased slightly to CNY 276,204,970.94 from CNY 281,335,036.35, a decline of 1.9%[22] - The company experienced a decrease in other comprehensive income attributable to the parent company, amounting to -5,520,604.79 CNY in Q1 2023, compared to 3,329,894.61 CNY in Q1 2022[27] - The company received 15,234,935.19 CNY in tax refunds during Q1 2023, an increase from 9,419,590.38 CNY in the previous year[30]

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号：2016-0203 | --- | --- | --- | --- | |----------------|-----------------------|-------------------------------------|------------------------------------------------| | | | | | | | √ | 特定对象调研 □分析师会议 | | | | □ | 媒体采访 □业绩说明会 | | | 投资者关系活动 | □ | 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | | | □其他 （请文字说明其他活动内容） | | | | | | 广发证券：计算机行业分析师 王文龙 王奇钰 | | | | 中泰证券：计算机行业研究员 李振亚 | | | 参与单位名称及 | | 计算机行业分析师 方闻千 | | | 人员姓名 | | 泰旸资产：高级研究员 赖燊生 | | | | | 浙江新干线传媒投资：投资经理 阮继祥 | | | 时间 | ...

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号：2016-0404 | --- | --- | --- | --- | --- | |----------------|------------|-------|---------------------------------------|--------------------------------------------| | | | | | | | | √ | | 特定对象调研 □分析师会议 | | | | □ | | 媒体采访 □业绩说明会 | | | 投资者关系活动 | □ | | 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 | | | | 广发证券： 王文龙 嘉实基金： 王寻恒 张晓东 | | 人员姓名 | | | 上银基金： 王 玮 方正证券： 张常新 | | | | | | 银华基金： 薄官辉 中银国际： 宋 彬 | | | | | | | 汇添富基金： 何 锐 国泰君安： 谭峰英 ...

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号：2016-0910 | --- | --- | --- | |----------------|------------------------------|------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动 | □ | 新闻发布会 □路演活动 | | 类别 | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 西南证券：熊 莉 | | | 人员姓名 | 华西证券：王 翠 | | | 时间 | 2016 年 9 月 14 | 日 | | 地点 | 杭州市莫干山路 | 1418-48 号（上城科技经济园） | | 上市公司接待人 | 财务总监兼董秘 周为利 | | | 员姓名 | 证券事务代表 夏亚芳 | | | 投资者关系活动 | 一、来访投资者签署《承诺书》 | | | 主要内容介绍 | 二 ...

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号：2016-0909 | --- | --- | --- | |----------------|------------------------------|------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 汇添富基金：何 锐 姚宗辉 | | | 人员姓名 | 中金公司：张景松 | | | 时间 | 2016 年 9 月 13 | 日 | | 地点 | 杭州市滨江区东信大道 座） | 66 号东方通信城 D 座（体验中心 B | | | 副董事长兼总经理 章笠中 | | | 上市公司接待人 | 财务总监兼董秘 周为利 | | | 员姓名 | 董事 孙新军 | | | | 证券事务代表 夏亚芳 | | ...

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号：2016-1015 | --- | --- | --- | |----------------|------------|--------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动 | □ | 新闻发布会 □路演活动 | | 类别 | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 华泰证券：郭雅丽；光大证券：卫书根；中信证券：张若 | | 人员姓名 | | 海；兴业证券：钱路丰；安信证券：凌 晨；海通证券：杨 | | | | 林、宋 茜；招商证券：宋兴未；中银国际证券：吴砚靖；长 | | | | 江证券：刘慧慧；广发证券：王文龙；浙商证券：耿军军； | | | | 东吴证券：朱悦如；汇丰晋信基金：汤 祺；巨柏基金：刘逢 | | | | 炜；兴业全球基金：陆士杰；长信基金：沈 佳 ...